Bronchoalveolar lavage fluid alteration in antioxidant and inflammatory status in lung cancer patients

2011 ◽  
Vol 22 (5) ◽  
pp. 522-526 ◽  
Author(s):  
T. Kontakiotis ◽  
K. Katsoulis ◽  
O. Hagizisi ◽  
M. Kougioulis ◽  
S. Gerou ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Inflammatory Status ◽  
Fluid Alteration

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

Low Neutral Endopeptidase Levels in Bronchoalveolar Lavage Fluid of Lung Cancer Patients

1999 ◽  
Vol 159 (3) ◽  
pp. 907-910 ◽  
Author(s):  
ANDREA J. COHEN ◽  
WILBUR A. FRANKLIN ◽  
CATHY MAGILL ◽  
JULIE SORENSON ◽  
YORK E. MILLER
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Neutral Endopeptidase ◽  
Lung Cancer Patients

Functional analysis of cells obtained from bronchoalveolar lavage fluid (BALF) of lung cancer patients

Life Sciences ◽  
2005 ◽  
Vol 76 (25) ◽  
pp. 2945-2951 ◽  
Author(s):  
Luciene Barbosa Anselmo ◽  
Jefferson Luiz Gross ◽  
Fabio Haddad ◽  
Daniel Deheinzelin ◽  
Riad Naim Younes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Functional Analysis ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients

CD4+/CD25 high /FoxP3+/CD127− regulatory T cells in bronchoalveolar lavage fluid of lung cancer patients

2016 ◽  
Vol 77 (10) ◽  
pp. 912-915 ◽  
Author(s):  
Iwona Osińska ◽  
Anna Stelmaszczyk-Emmel ◽  
Małgorzata Polubiec-Kownacka ◽  
Dariusz Dziedzic ◽  
Joanna Domagała-Kulawik
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document